• Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial Stocktwits Thu, 09 Jul 2026 04:20:49 GMT
• Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. – NASDAQ:APRE TradingView Mon, 06 Jul 2026 11:14:58 GMT
• aprea therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial Stocktwits Sun, 05 Jul 2026 14:09:54 GMT
• Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) TradingView Fri, 26 Jun 2026 17:31:30 GMT
• aprea therapeutics inc (apre) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 24 Jun 2026 07:00:00 GMT
• aprea therapeutics inc (apre) risk assessment: volatility, financial risk & investment risk TradingKey Tue, 23 Jun 2026 07:42:19 GMT
• Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics BioPharm International Mon, 22 Jun 2026 07:00:00 GMT
• aprea therapeutics inc (apre) earnings forecast: future eps & revenue growth estimates TradingKey Mon, 22 Jun 2026 07:00:00 GMT
• aprea shareholders approve directors, reverse split flexibility The Globe and Mail Thu, 18 Jun 2026 21:14:00 GMT
• aprea therapeutics inc (apre) risk assessment: volatility, financial risk & investment risk TradingKey Thu, 18 Jun 2026 09:46:11 GMT
• aprea therapeutics inc (apre) valuation: pe, pb & fair value analysis TradingKey Thu, 18 Jun 2026 09:38:43 GMT
• Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting Minichart Thu, 18 Jun 2026 07:00:00 GMT
• aprea therapeutics inc (apre) technical analysis: support, resistance, indicators & moving averages TradingKey Thu, 18 Jun 2026 05:54:01 GMT
• aprea therapeutics inc (apre) financial health: profitability & balance sheet analysis TradingKey Thu, 18 Jun 2026 04:17:13 GMT
• aprea therapeutics inc (apre) earnings forecast: future eps & revenue growth estimates TradingKey Thu, 18 Jun 2026 03:02:42 GMT
• aprea therapeutics shareholders approve director elections and reverse stock split by investing.com Investing.com South Africa Thu, 18 Jun 2026 00:26:03 GMT
• aprea therapeutics inc (apre) shareholder structure: major shareholders & institutional holdings TradingKey Wed, 17 Jun 2026 16:58:16 GMT
• aprea therapeutics inc (apre) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Wed, 17 Jun 2026 16:55:09 GMT
• aprea therapeutics inc (apre) dividends & stock splits: historical payouts and event timeline TradingKey Wed, 17 Jun 2026 16:53:35 GMT
• aprea therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial Stocktwits Wed, 17 Jun 2026 15:49:42 GMT
• Aprea Therapeutics shareholders approve director elections and reverse stock split Investing.com Wed, 17 Jun 2026 07:00:00 GMT
• aprea shareholders approve directors, reverse split flexibility TipRanks Wed, 17 Jun 2026 07:00:00 GMT
• [form 4] aprea therapeutics, inc. insider trading activity Stock Titan Wed, 17 Jun 2026 07:00:00 GMT
• apre: all agenda items, including director elections and reverse stock split, were approved TradingView Tue, 16 Jun 2026 14:10:30 GMT
• apre q1 2026 earnings: narrower loss exceeds estimates but investor sentiment weakens - revenue growth outlook newsline.com Mon, 15 Jun 2026 09:48:16 GMT
• Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5 Moomoo Mon, 15 Jun 2026 07:00:00 GMT
• aprea therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial Stocktwits Sat, 13 Jun 2026 17:17:29 GMT
• this aprea therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for thursday MSN Thu, 11 Jun 2026 22:41:34 GMT
• apre q1 2026 earnings: narrower-than-expected loss boosts investor sentiment - earnings seasonality newsline.com Wed, 10 Jun 2026 09:32:42 GMT
• apre q1 2026 earnings: narrower-than-expected net loss despite no revenue - guidance revision trend newsline.com Tue, 09 Jun 2026 19:43:00 GMT
• aprea therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial Stocktwits Tue, 09 Jun 2026 10:15:51 GMT
• apre q1 2026 earnings: narrower loss surpasses expectations amid ongoing clinical development - analyst consensus shift newsline.com Tue, 09 Jun 2026 01:41:28 GMT
• aprea reports early tumor responses in phase 1 apr-1051 study MyChesCo Mon, 08 Jun 2026 07:00:00 GMT
• apre q1 2026 earnings: narrower loss surpasses expectations amid ongoing clinical development - analyst consensus shift newsline.com Mon, 08 Jun 2026 07:00:00 GMT
• aprea therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial Stocktwits Sun, 07 Jun 2026 19:40:49 GMT
• apre q1 2026 earnings: narrower-than-expected loss as clinical pipeline advances - special dividend alert newsline.com Sat, 06 Jun 2026 07:00:00 GMT
• APRE Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Advances - One-Time Gain Impact dars.gov.et Thu, 04 Jun 2026 07:00:00 GMT
• aprea therapeutics (apre) edges higher: modest gain amid tight trading range - up down ratio newsline.com Thu, 04 Jun 2026 07:00:00 GMT
• apre q1 2026 earnings: eps beats estimates but no revenue reported; stock slides 1.95% - profit warning alert newsline.com Tue, 02 Jun 2026 07:00:00 GMT
• h.c. wainwright maintains aprea therapeutics(apre.us) with buy rating, maintains target price $1.2 Moomoo Mon, 01 Jun 2026 16:32:00 GMT
• aprea's wee1 drug shows early promise in hard-to-treat cancers BriefGlance Mon, 01 Jun 2026 13:51:00 GMT
• aprea therapeutics presents updated phase 1 data on wee1 inhibitor apr-1051 at asco 2026, demonstrating early monotherapy activity... The Manila Times Mon, 01 Jun 2026 12:20:52 GMT
• cancer trial drug apr-1051 posts partial responses at asco 2026 Stock Titan Mon, 01 Jun 2026 12:00:00 GMT
• pantginis reiterates buy on apr-1051 developer, keeps $1.20 price target after encouraging asco data and superior safety profile TipRanks Mon, 01 Jun 2026 07:00:00 GMT
• apre q1 2026 earnings: eps beats estimates by 6.22% as pre-revenue biotech focuses on pipeline - earnings growth analysis newsline.com Mon, 01 Jun 2026 07:00:00 GMT
• aprea therapeutics (apre) slides 5.86% as stock tests key support at $0.80 - pcr spike newsline.com Mon, 01 Jun 2026 07:00:00 GMT
• aprea therapeutics (apre) slips 4% as stock nears critical $0.85 support level - overbought signal alerts newsline.com Sat, 30 May 2026 07:00:00 GMT
• aprea therapeutics (apre) edges higher amid light trading; key resistance at $0.99 in focus - obv divergence The Legal Advocate Thu, 28 May 2026 19:36:45 GMT
• aprea therapeutics (apre) edges higher amid low volume trading - growth etf The Legal Advocate Thu, 28 May 2026 15:31:17 GMT
• Aprea Therapeutics (APRE) Gains 2.78% as Shares Approach Key Resistance at $0.99 - Day Trade Opportunities dars.gov.et Thu, 28 May 2026 07:00:00 GMT
• aprea therapeutics inc. (apre) q1 2026 earnings: narrower-than-expected loss highlights cost discipline amid clinical progress - a... newsline.com Thu, 28 May 2026 07:00:00 GMT
• aprea therapeutics (apre) upgraded to buy: here's what you should know MSN Mon, 25 May 2026 06:46:42 GMT
• apre q1 2026 earnings: narrower loss beats estimates, stock rises 2.15% - forward eps estimate newsline.com Sun, 24 May 2026 02:38:31 GMT
• aprea therapeutics (apre) upgraded to buy: here's what you should know MSN Sat, 23 May 2026 10:15:38 GMT
• apre q1 2026 earnings: narrower-than-expected loss highlights cost discipline - revenue warning signal newsline.com Sat, 23 May 2026 07:00:00 GMT
• wedbush maintains aprea therapeutics(apre.us) with buy rating, cuts target price to $6 富途牛牛 Fri, 22 May 2026 18:38:00 GMT
• aprea therapeutics (apre) upgraded to buy: here's what you should know MSN Fri, 22 May 2026 10:41:46 GMT
• apre q1 2026 earnings: eps beat on reduced loss per share - basic eps analysis newsline.com Fri, 22 May 2026 07:00:00 GMT
• aprea therapeutics (apre) upgraded to buy: here's what you should know sharewise.com Thu, 21 May 2026 07:00:00 GMT
• this aprea therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for thursday MSN Wed, 20 May 2026 04:06:38 GMT
• aprea therapeutics 1q research and development expenses $1.6m >apre Moomoo Fri, 15 May 2026 18:17:26 GMT
• aprea therapeutics - files for resale of up to 5.5 million shares by selling stockholders - sec filing TradingView Fri, 15 May 2026 07:00:00 GMT
• [424b7] aprea therapeutics, inc. prospectus filed pursuant to rule 424(b)(7) Stock Titan Fri, 15 May 2026 07:00:00 GMT
• vestal point reports 9.9% stake in aprea therapeutics (nasdaq: apre) Stock Titan Fri, 15 May 2026 07:00:00 GMT
• wedbush maintains aprea therapeutics(apre.us) with buy rating, cuts target price to $6 Moomoo Fri, 15 May 2026 01:17:26 GMT
• maxim group maintains aprea therapeutics(apre.us) with buy rating, maintains target price $5 Moomoo Fri, 15 May 2026 01:16:47 GMT
• press release: aprea therapeutics reports first quarter 2026 financial results and provides a corporate update Moomoo Thu, 14 May 2026 15:10:29 GMT
• wedbush adjusts price target on aprea therapeutics to $6 from $7, maintains outperform rating Moomoo Thu, 14 May 2026 10:18:37 GMT
• aprea therapeutics, inc. q1 2026 10-q report – financials, risk factors, and forward-looking statements Minichart Thu, 14 May 2026 07:00:00 GMT
• wedbush maintains aprea therapeutics(apre.us) with buy rating, cuts target price to $6 富途牛牛 Thu, 14 May 2026 07:00:00 GMT
• aprea therapeutics price target lowered to $6 from $7 at wedbush TipRanks Thu, 14 May 2026 07:00:00 GMT
• analyst reiterates buy on aprea as apr-1051 data and cash runway support unchanged $5 price target TipRanks Thu, 14 May 2026 07:00:00 GMT
• aprea therapeutics, inc. q1 2026 10-q report – financials, risk factors, and forward-looking statements Minichart Wed, 13 May 2026 17:54:00 GMT
• this aprea therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for thursday MSN Wed, 13 May 2026 13:23:29 GMT
• aprea therapeutics reports q1 eps (22c) vs. (66c) last year TipRanks Wed, 13 May 2026 13:00:55 GMT
• aprea therapeutics (nasdaq: apre) trims q1 loss and raises over $34m to extend cash runway Stock Titan Wed, 13 May 2026 10:46:09 GMT
• aprea therapeutics, inc. reports earnings results for the first quarter ended march 31, 2026 marketscreener.com Wed, 13 May 2026 10:46:00 GMT
• 8-k: aprea therapeutics reports first quarter 2026 financial results and provides a corporate update - moomoo Moomoo Wed, 13 May 2026 10:35:55 GMT
• aprea therapeutics 1q research and development expenses $1.6m >apre Moomoo Wed, 13 May 2026 10:30:00 GMT
• Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher ChartMill Wed, 13 May 2026 07:00:00 GMT
• Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early ... Quiver Quantitative Wed, 13 May 2026 07:00:00 GMT
• Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary TradingView Wed, 13 May 2026 07:00:00 GMT
• aprea therapeutics inc reports results for the quarter ended march 31 - earnings summary TradingView Wed, 13 May 2026 07:00:00 GMT
• aprea therapeutics ($apre) releases q1 2026 earnings Quiver Quantitative Wed, 13 May 2026 07:00:00 GMT
• early tumor responses and $30m cash boost for aprea cancer drug Stock Titan Wed, 13 May 2026 07:00:00 GMT
• aprea therapeutics reports q1 2026 results: $30m financing boosts apr-1051 clinical progress and extends cash runway to 2028 Minichart Wed, 13 May 2026 07:00:00 GMT
• aprea (nasdaq: apre) extends cash runway and reports q1 2026 results Stock Titan Wed, 13 May 2026 07:00:00 GMT
• aprea therapeutics q1 net loss narrows as r&d expenses fall TradingView Wed, 13 May 2026 07:00:00 GMT
• aprea therapeutics highlights q1 2026 results and clinical progress TipRanks Wed, 13 May 2026 07:00:00 GMT
• a breakout year for wee1? oppenheimer sees 6x upside in this under-the-radar biotech Barchart.com Tue, 12 May 2026 13:39:46 GMT
• apre (aprea) beats q4 earnings by 20%, but shares fall 2.3% amid growth concerns. - annual financial report newsline.com Mon, 11 May 2026 07:00:00 GMT
• two life sciences companies with doylestown connections raise $119m MSN Mon, 11 May 2026 01:25:13 GMT
• apre (aprea) q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%. - put/call ratio newser.com Sat, 09 May 2026 05:38:27 GMT
• aprea therapeutics inc expected to post a loss of 23 cents a share - earnings preview TradingView Fri, 08 May 2026 15:37:19 GMT
• apre (aprea) q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%. - eps revision trend The Legal Advocate Fri, 08 May 2026 07:00:00 GMT
• aprea therapeutics initiated with an outperform at oppenheimer TipRanks Fri, 08 May 2026 01:28:40 GMT
• oppenheimer initiates aprea stock with outperform on wee1 inhibitor potential Investing.com Thu, 07 May 2026 07:00:00 GMT
• oppenheimer initiates coverage of aprea therapeutics (apre) with outperform recommendation MSN Thu, 07 May 2026 07:00:00 GMT
• this aprea therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for thursday Benzinga Thu, 07 May 2026 07:00:00 GMT
• aprea therapeutics initiated with an outperform at oppenheimer TipRanks Thu, 07 May 2026 07:00:00 GMT
• oppenheimer initiates aprea therapeutics at outperform with $5 price target marketscreener.com Thu, 07 May 2026 07:00:00 GMT
• two life sciences companies with doylestown connections raise $119m MSN Thu, 07 May 2026 02:04:39 GMT
• apre | aprea therapeutics, inc. common executive compensation Quiver Quantitative Sun, 03 May 2026 14:22:06 GMT
• apre stock price, quote & chart | aprea therapeutics inc (nasdaq:apre) ChartMill Fri, 01 May 2026 07:00:00 GMT
• two life sciences companies with doylestown connections raise $119m MSN Fri, 01 May 2026 02:23:12 GMT
• two life sciences companies with doylestown connections raise $119m MSN Thu, 30 Apr 2026 21:38:30 GMT
• apre sec filings - aprea therapeutics, inc. 10-k, 10-q, 8-k forms Stock Titan Thu, 30 Apr 2026 16:56:43 GMT
• reverse split and director votes in aprea therapeutics (nasdaq: apre) 2026 proxy Stock Titan Thu, 30 Apr 2026 07:00:00 GMT
• 74.35m shares registered for resale by aprea therapeutics (nasdaq: apre) Stock Titan Wed, 29 Apr 2026 07:00:00 GMT
• two life sciences companies with doylestown connections raise $119m MSN Tue, 28 Apr 2026 17:30:08 GMT
• catalym names christian schade as board chairman by investing.com Investing.com India Tue, 28 Apr 2026 11:24:02 GMT
• catalym picks ex-aprea ceo christian schade to chair board Stock Titan Tue, 28 Apr 2026 11:03:43 GMT
• aprea therapeutics (nasdaq: apre) reporting group discloses 9.9% stake Stock Titan Mon, 27 Apr 2026 07:00:00 GMT
• two life sciences companies with doylestown connections raise $119m MSN Mon, 27 Apr 2026 03:22:30 GMT
• two life sciences companies with doylestown connections raise $119m MSN Sun, 26 Apr 2026 17:30:40 GMT
• apre forecast, price target & analyst ratings | aprea therapeutics inc (nasdaq:apre) ChartMill Fri, 24 Apr 2026 07:00:00 GMT
• aprea therapeutics (apre) price target decreased by 17.50% to 4.49 MSN Thu, 23 Apr 2026 15:46:54 GMT
• aprea (apre): buy, sell, or hold? | q4 2025: eps beats forecasts - ev/ebitda Xã Vĩnh Công Thu, 23 Apr 2026 04:29:45 GMT
• aprea (apre): buy, sell, or hold? | q4 2025: eps beats forecasts - ev/ebitda Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 23:57:42 GMT
• aprea therapeutics (nasdaq: apre) registers 74.35m shares for resale by investors Stock Titan Wed, 22 Apr 2026 07:00:00 GMT
• greater philadelphia-based aprea therapeutics raises $30m to extend runway and reposition its precision oncology bet biobuzz.io Wed, 22 Apr 2026 01:51:31 GMT
• Early human data on Aprea cancer drug lands ASCO 2026 poster slot Stock Titan Tue, 21 Apr 2026 07:00:00 GMT
• Greater Philadelphia-based Aprea Therapeutics Raises $30M to Extend Runway and Reposition Its Precision Oncology Bet BioBuzz Tue, 21 Apr 2026 07:00:00 GMT
• aprea therapeutics abstract accepted at asco meeting in may Investing.com Tue, 21 Apr 2026 07:00:00 GMT
• aprea therapeutics announces acceptance of abstract for phase 1 study of wee1 inhibitor apr-1051 at asco 2026 Quiver Quantitative Tue, 21 Apr 2026 07:00:00 GMT
• aprea therapeutics (nasdaq: apre) seeks board authority for 1‑for‑3–1‑for‑8 reverse split Stock Titan Mon, 20 Apr 2026 07:00:00 GMT
• aprea (apre) stock: why it matters now (eye on rally) 2026-04-18 - revenue weighted newsline.com Sat, 18 Apr 2026 07:00:00 GMT
• 10 health care stocks moving in friday's intraday session - aligos therapeutics (nasdaq:algs), aprea ther Benzinga Fri, 17 Apr 2026 07:00:00 GMT
• zentalis surges 20% on wee1 inhibitor dose selection—but is aprea the real winner in this space? Barchart Fri, 17 Apr 2026 07:00:00 GMT
• apre forecast, price target & analyst ratings | aprea therapeutics inc (nasdaq:apre) ChartMill Fri, 17 Apr 2026 07:00:00 GMT
• aprea therapeutics (apre) price target decreased by 17.50% to 4.49 MSN Thu, 16 Apr 2026 17:04:19 GMT
Aprea Therapeutics, Inc(NASDAQ:APRE) 
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical d...
Website: http://www.aprea.com
Founded: 2006
IPO Price: $15 (Oct 03, 2019)
Full Time Employees: 13
CEO: Christian S. Schade
Sector: Healthcare
Industry: Biotechnology